Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DR6E | ISIN: CA60255C8850 | Ticker-Symbol: MMQ
Tradegate
20.12.24
19:13 Uhr
7,030 Euro
+0,170
+2,48 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
MIND MEDICINE MINDMED INC Chart 1 Jahr
5-Tage-Chart
MIND MEDICINE MINDMED INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,7656,93521.12.
6,7906,93020.12.

Aktuelle News zur MIND MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoMindMed wird in den Nasdaq Biotechnology Index aufgenommen5
DoMindMed joins Nasdaq Biotechnology Index1
DoMind Medicine (MindMed) Inc.: MindMed to Be Added to the Nasdaq Biotechnology Index226Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
DiMindMed begins phase 3 study of MM120 for anxiety disorder13
MoMind Medicine (MindMed) Inc.: MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)230- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12...
► Artikel lesen
MIND MEDICINE Aktie jetzt für 0€ handeln
MoMind Medicine Inc. - 8-K, Current Report4
11.12.Mind Medicine: MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress210Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
06.12.MindMed receives innovation passport for GAD therapy from UK MHRA2
05.12.Mind Medicine-Direktor David Gryska erwirbt Aktien im Wert von 17.925 US-Dollar3
05.12.MindMed erhält britischen Innovationspass für GAD-Behandlung8
05.12.MindMed gains UK Innovation Passport for GAD treatment2
05.12.Mind Medicine Inc.: MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)281Innovation Passport Designation Aims to Accelerate Time to Market and Facilitate Patient Access to Innovative Medicines - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed")...
► Artikel lesen
03.12.MindMed appoints new VP of R&D Strategy4
03.12.MindMed ernennt neuen Vizepräsidenten für F&E-Strategie4
03.12.Mind Medicine Inc.: MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy325Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
02.12.Mind Medicine Inc.: MindMed Announces New Employee Inducement Grants148Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
30.11.Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 3% - What's Next?3
18.11.MindMed ernennt neuen Leiter für Regulierung und Qualität22
18.11.MindMed appoints new regulatory and quality chief6
18.11.Mind Medicine (MindMed) Inc.: MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer296Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
Seite:  Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1